Active ingredientTazemetostatCat. No. P-T024-001CAS 1403254-99-8Family · Pharmaceutical analytical standards
Tazemetostat
A selective inhibitor of EZH2, an enzyme that adds methyl groups to histones and regulates gene activity: approved in the United States in January 2020 for epithelioid sarcoma, it was voluntarily withdrawn from the market in 2026. This family brings together the active ingredient and labelled standards.
Did you know?It was the first treatment approved specifically for epithelioid sarcoma, a rare soft tissue cancer, and the first medicine of its class.
Go to the active ingredient →Active ingredientTazemetostatCat. No. P-T024-001CAS 1403254-99-8
Isotopically labelledTazemetostat-d8Cat. No. P-T024-002No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.